

CITATION REPORT

List of articles citing

Heterogeneity in tuberculosis pathology,
microenvironments and therapeutic responses

DOI: 10.1111/imr.12252

Immunological Reviews, 2015, 264, 288-307.

Source: <https://exaly.com/paper-pdf/62341874/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
264	A far-red fluorescent probe for flow cytometry and image-based functional studies of xenobiotic sequestering macrophages. 2015 , 87, 855-67		20
263	Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?. <i>Frontiers in Microbiology</i> , 2015 , 6, 1117	5.7	4
262	A Novel Reading Scheme for Assessing the Extent of Radiographic Abnormalities and Its Association with Disease Severity in Sputum Smear-Positive Tuberculosis: An Observational Study in Hyderabad/India. 2015 , 10, e0138070		7
261	Eagle Effect in Nonreplicating Persister Mycobacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7786-9	5.9	11
260	What can immunology contribute to the control of the world's leading cause of death from bacterial infection?. <i>Immunological Reviews</i> , 2015 , 264, 2-5	11.3	4
259	Activity of lipophilic and hydrophilic drugs against dormant and replicating Mycobacterium tuberculosis. 2015 , 68, 711-4		36
258	Treatment of Tuberculosis. 2015 , 373, 2149-60		204
257	Boromycin Kills Mycobacterial Persisters without Detectable Resistance. <i>Frontiers in Microbiology</i> , 2016 , 7, 199	5.7	50
256	Mild Nutrient Starvation Triggers the Development of a Small-Cell Survival Morphotype in Mycobacteria. <i>Frontiers in Microbiology</i> , 2016 , 7, 947	5.7	24
255	Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis. 2016 , 2, 616-626		59
254	Structure of the Essential FadD32 Enzyme: A Promising Drug Target for Treating Tuberculosis. 2016 , 2, 579-591		20
253	Mouse model of pulmonary cavitary tuberculosis and expression of matrix metalloproteinase-9. 2016 , 9, 779-88		39
252	Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models. 2017 , 72, 770-777		19
251	New Evidence for the Complexity of the Population Structure of Mycobacterium tuberculosis Increases the Diagnostic and Biologic Challenges. 2016 , 194, 1448-1451		18
250	Regulation of Immunity to Tuberculosis. 2016 , 4,		13
249	Membrane-targeting AM-0016 kills mycobacterial persisters and shows low propensity for resistance development. 2016 , 11, 643-50		28
248	2-Aryl-8-aza-3-deazaadenosine analogues of 5'-O-[N-(salicyl)sulfamoyl]adenosine: Nucleoside antibiotics that block siderophore biosynthesis in Mycobacterium tuberculosis. 2016 , 24, 3133-43		13

247	CD4+ T-cell-independent mechanisms suppress reactivation of latent tuberculosis in a macaque model of HIV coinfection. 2016 , 113, E5636-44	84
246	Predictive value of serum bradykinin and desArg-bradykinin levels for chemotherapeutic responses in active tuberculosis patients: A retrospective case series. 2016 , 101S, S109-S118	8
245	Sputum is a surrogate for bronchoalveolar lavage for monitoring Mycobacterium tuberculosis transcriptional profiles in TB patients. 2016 , 100, 89-94	16
244	Mycobacterium tuberculosis gene expression at different stages of hypoxia-induced dormancy and upon resuscitation. 2016 , 54, 565-72	26
243	Understanding the pathophysiology of the human TB lung granuloma using in vitro granuloma models. 2016 , 11, 1073-89	10
242	Characterization of tuberculous granulomas in different stages of progression and associated tertiary lymphoid tissue in goats experimentally infected with Mycobacterium avium subsp. hominissuis. 2016 , 47, 41-51	4
241	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. 2016 , 63, e147-e195	586
240	Diversity of Human and Macaque Airway Immune Cells at Baseline and during Tuberculosis Infection. 2016 , 55, 899-908	13
239	Host-Pathogen Interactions in Tuberculosis: The Evolving Story. 2016 , 214, 1137-8	1
238	Phenotypic Heterogeneity in Mycobacterium tuberculosis. 2016 , 4,	34
237	Experimental Infection of Goats with Mycobacterium avium subsp. hominissuis: a Model for Comparative Tuberculosis Research. 2016 , 155, 218-230	11
236	Experimental models of sarcoidosis. 2016 , 22, 492-9	5
235	Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5198-207	5.9 64
234	Multiscale Model of Mycobacterium tuberculosis Infection Maps Metabolite and Gene Perturbations to Granuloma Sterilization Predictions. 2016 , 84, 1650-1669	28
233	Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Infected C3HeB/FeJ Mice. 2016 , 2, 251-267	73
232	Synthesis and pharmacological evaluation of nucleoside prodrugs designed to target siderophore biosynthesis in Mycobacterium tuberculosis. 2016 , 24, 1314-21	15
231	Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 735-43	5.9 47
230	Tuberculosis as a three-act play: A new paradigm for the pathogenesis of pulmonary tuberculosis. 2016 , 97, 8-17	90

229	Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review. 2016 , 38, 167-83		71
228	Mouse models of human TB pathology: roles in the analysis of necrosis and the development of host-directed therapies. 2016 , 38, 221-37		84
227	Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis. 2016 , 213, 618-27		22
226	Pathology and immune reactivity: understanding multidimensionality in pulmonary tuberculosis. 2016 , 38, 153-66		87
225	Molecular mechanisms of action, resistance, detection to the first-line anti tuberculosis drugs: Rifampicin and pyrazinamide in the post whole genome sequencing era. 2017 , 105, 96-107		24
224	Digitally Barcoding Reveals Infection Dynamics in the Macaque Model of Tuberculosis. <i>MBio</i> , 2017 , 8,	7.8	91
223	Healthcare-Associated Mycobacterium bovis-Bacille Calmette-Guérin (BCG) Infection in Cancer Patients Without Prior BCG Instillation. 2017 , 65, 1136-1143		2
222	Positron Emission Tomography Imaging of Macaques with Tuberculosis Identifies Temporal Changes in Granuloma Glucose Metabolism and Integrin α ₄ -Expressing Immune Cells. 2017 , 199, 806-815		35
221	Metabolic anticipation in Mycobacterium tuberculosis. 2017 , 2, 17084		52
220	A review of computational and mathematical modeling contributions to our understanding of Mycobacterium tuberculosis within-host infection and treatment. 2017 , 3, 170-185		31
219	Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions. 2017 , 5,		26
218	The within-host population dynamics of Mycobacterium tuberculosis vary with treatment efficacy. 2017 , 18, 71		60
217	Selective Killing of Dormant Mycobacterium tuberculosis by Marine Natural Products. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	28
216	Accelerating tuberculosis vaccine trials with diagnostic and prognostic biomarkers. 2017 , 16, 845-853		7
215	Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives. 2017 , 41, 354-373		153
214	Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	17
213	The long and winding road to inhaled TB therapy: not only the bug's fault. 2017 , 43, 347-363		13
212	Histopathology of vaccine-preventable diseases. 2017 , 70, 109-122		7

211	Asymptomatic pulmonary tuberculosis mimicking lung cancer on imaging: A retrospective study. 2017 , 14, 2180-2188		12
210	Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD. 2017 , 3, 807-819		40
209	Heterogeneity of Salmonella-host interactions in infected host tissues. 2017 , 39, 57-63		20
208	Profiling of in vitro activities of urea-based inhibitors against cysteine synthases from <i>Mycobacterium tuberculosis</i> . 2017 , 27, 4582-4587		10
207	NOS2-deficient mice with hypoxic necrotizing lung lesions predict outcomes of tuberculosis chemotherapy in humans. 2017 , 7, 8853		15
206	Anaerobic <i>Mycobacterium tuberculosis</i> Cell Death Stems from Intracellular Acidification Mitigated by the DosR Regulon. 2017 , 199,		6
205	Heterogeneity in tuberculosis. 2017 , 17, 691-702		213
204	Recent mouse models and vaccine candidates for preventing chronic/latent tuberculosis infection and its reactivation. 2017 , 75,		3
203	The Capacity of To Survive Iron Starvation Might Enable It To Persist in Iron-Deprived Microenvironments of Human Granulomas. <i>MBio</i> , 2017 , 8,	7.8	57
202	<i>Mycobacteria</i> . 2017 , 1645-1659.e2		3
201	The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis. 2017 , 3, 5-17		62
200	<i>Mycobacterial Biofilms: Revisiting Tuberculosis Bacilli in Extracellular Necrotizing Lesions</i> . 2017 , 533-539		1
199	Regulation of Immunity to Tuberculosis. 2017 , 73-93		1
198	Phenotypic Heterogeneity in <i>Mycobacterium tuberculosis</i> . 2017 , 671-697		1
197	Submillisievert Computed Tomography of the Chest in Contact Investigation for Drug-Resistant Tuberculosis. 2017 , 32, 1779-1783		6
196	Horizontal acquisition of a hypoxia-responsive molybdenum cofactor biosynthesis pathway contributed to <i>Mycobacterium tuberculosis</i> pathoadaptation. <i>PLoS Pathogens</i> , 2017 , 13, e1006752	7.6	18
195	Metabolic adaptation of two in silico mutants of <i>Mycobacterium tuberculosis</i> during infection. 2017 , 11, 107		12
194	Structure Guided Lead Generation toward Nonchiral <i>M. tuberculosis</i> Thymidylate Kinase Inhibitors. 2018 , 61, 2753-2775		20

193	Fluorescent Mycobacterium tuberculosis reporters: illuminating host-pathogen interactions. 2018 , 76,		21
192	Visualization of Mycobacterial Biomarkers and Tuberculosis Drugs in Infected Tissue by MALDI-MS Imaging. 2018 , 90, 6275-6282		35
191	Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	12
190	NTM drug discovery: status, gaps and the way forward. 2018 , 23, 1502-1519		106
189	Potential Immunological Biomarkers for Detection of Mycobacterium tuberculosis Infection in a Setting Where M. tuberculosis Is Endemic, Ethiopia. 2018 , 86,		8
188	Latent tuberculosis infection and associated risk indicators in pastoral communities in southern Ethiopia: a community based cross-sectional study. 2018 , 18, 266		9
187	Combinations of Respiratory Chain Inhibitors Have Enhanced Bactericidal Activity against Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	24
186	Host-directed therapies for bacterial and viral infections. 2018 , 17, 35-56		280
185	Diagnostic value of Tc-ethambutol scintigraphy in tuberculosis: compared to microbiological and histopathological tests. 2018 , 32, 60-68		10
184	Tuberculosis. 2018 , 48, 108-130		50
183	Monitoring Response to Therapy. 2018 , 48, 166-181		26
182	Mycobacterial Diseases. 2018 , 201-216		2
181	An explant technique for high-resolution imaging and manipulation of mycobacterial granulomas. 2018 , 15, 1098-1107		21
180	Noninvasive C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. 2018 , 10,		46
179	Accessible and distinct decoquinolate derivatives active against Mycobacterium tuberculosis and apicomplexan parasites. 2018 , 1,		14
178	The End of the Binary Era: Revisiting the Spectrum of Tuberculosis. 2018 , 201, 2541-2548		54
177	Human Monocytic Suppressive Cells Promote Replication of and Alter Stability of Generated Granulomas. <i>Frontiers in Immunology</i> , 2018 , 9, 2417	8.4	19
176	Drug permeation and metabolism in Mycobacterium tuberculosis: Prioritising local exposure as essential criterion in new TB drug development. 2018 , 70, 926-937		17

175	Impact of immunopathology on the antituberculous activity of pyrazinamide. 2018 , 215, 1975-1986	19
174	Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. 2018 , 31,	171
173	Advanced cellular systems to study tuberculosis treatment. 2018 , 42, 16-21	5
172	Delineating the Physiological Roles of the PE and Catalytic Domains of LipY in Lipid Consumption in Mycobacterium-Infected Foamy Macrophages. 2018 , 86,	21
171	Potential of DosR and Rpf antigens from Mycobacterium tuberculosis to discriminate between latent and active tuberculosis in a tuberculosis endemic population of Medellin Colombia. 2018 , 18, 26	26
170	The present state of the tuberculosis drug development pipeline. 2018 , 42, 81-94	44
169	Host-pathogen redox dynamics modulate Mycobacterium tuberculosis pathogenesis. 2018 , 76,	14
168	Ex vivo expansion of alveolar macrophages with Mycobacterium tuberculosis from the resected lungs of patients with pulmonary tuberculosis. 2018 , 13, e0191918	8
167	Extra Pulmonary Tuberculosis: An Overview. 2019 ,	3
166	Metabolism. 2019 , 7,	7
165	Differential determinants of virulence in two Colombian clinical isolates of the LAM09 family. 2019 , 10, 695-710	11
164	mSphere of Influence: Clearing a Path for High-Resolution Visualization of Host-Pathogen Interactions. 2019 , 4,	
163	Radiosynthesis and PET Bioimaging of Br-Bedaquiline in a Murine Model of Tuberculosis. 2019 , 5, 1996-2002	12
162	Targeting drugs for tuberculosis. 2019 , 364, 1234-1235	1
161	Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?. 2019 , 29, 126731	9
160	Modelling Bovine Granuloma Formation In Vitro upon Infection with Subspecies. 2019 , 6,	4
159	Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs. 2019 , 36, 166	18
158	Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating. 2019 , 5, 1433-1445	7

157	Quantitative assessment of the activity of antituberculosis drugs and regimens. 2019 , 17, 449-457		0
156	A physicist's view of the similarities and differences between tuberculosis and cancer. 2019 , 534, 120761		1
155	The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	5
154	A biosafety algorithm for the protection of pathology staff during intraoperative examinations of pulmonary lesions. 2019 , 69, 211-218		1
153	Single-Cell Metabolism and Stress Responses in Complex Host Tissues. 2019 , 7,		5
152	An Observational Case-Control Study to Determine Human Immunodeficiency Virus and Host Factor Influence on Biomarker Distribution and Serodiagnostic Potential in Adult Pulmonary Tuberculosis. 2019 , 4,		1
151	Novel MenA Inhibitors Are Bactericidal against and Synergize with Electron Transport Chain Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	17
150	Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	11
149	Humanized Mouse Model Mimicking Pathology of Human Tuberculosis for Evaluation of Drug Regimens. <i>Frontiers in Immunology</i> , 2019 , 10, 89	8.4	8
148	Function, essentiality, and expression of cytochrome P450 enzymes and their cognate redox partners in Mycobacterium tuberculosis: are they drug targets?. 2019 , 103, 3597-3614		16
147	Mycobacterium tuberculosis Metabolism. 2019 , 1107-1128		
146	Molecular Imaging: a Novel Tool To Visualize Pathogenesis of Infections. <i>MBio</i> , 2019 , 10,	7.8	17
145	Rewiring of Metabolic Network in During Adaptation to Different Stresses. <i>Frontiers in Microbiology</i> , 2019 , 10, 2417	5.7	14
144	Tuberculosis Presenting as Isolated Wrist Swelling: A Case Report and Review of Literature. 2019 , 2019, 4916157		
143	X-ray-based virtual slicing of TB-infected lungs. 2019 , 9, 19404		2
142	Mechanism of Fluorinated Anthranilate-Induced Growth Inhibition in Mycobacterium tuberculosis. 2019 , 5, 55-62		11
141	Tuberculosis susceptibility and protection in children. 2019 , 19, e96-e108		40
140	The mystery of tuberculosis pathogenesis from the perspective of T regulatory cells. 2020 , 23, 100632		6

139	Reconsidering the Optimal Immune Response to. 2020 , 201, 407-413		14
138	Serum human epididymis protein 4 concentrations are associated with severity of patients with pulmonary tuberculosis. 2020 , 502, 255-260		1
137	Mycobacterium tuberculosis HN878 Infection Induces Human-Like B-Cell Follicles in Mice. 2020 , 221, 1636-1646		6
136	Omega-3 Fatty Acid and Iron Supplementation Alone, but Not in Combination, Lower Inflammation and Anemia of Infection in -Infected Mice. 2020 , 12,		6
135	Salmonella Single-Cell Metabolism and Stress Responses in Complex Host Tissues. 2020 , 167-177		
134	Technical and Anatomical Considerations for Reproducible Inactivation of Large Animal Carcasses by Steam Sterilization. 2020 , 153567602091963		
133	Is targeting dysregulation in apoptosis splice variants in Mycobacterium tuberculosis (MTB) host interactions and splicing factors resulting in immune evasion by MTB strategies a possibility?. 2020 , 124, 101964		1
132	Luteolin-mediated Kv1.3 K+ channel inhibition augments BCG vaccine efficacy against tuberculosis by promoting central memory T cell responses in mice. <i>PLoS Pathogens</i> , 2020 , 16, e1008887	7.6	4
131	Relevance of the Warburg Effect in Tuberculosis for Host-Directed Therapy. 2020 , 10, 576596		11
130	Effects of Cigarette Smoke Condensate on Growth and Biofilm Formation by. 2020 , 2020, 8237402		3
129	Histopathological and microbiological study of porcine lymphadenitis: contributions to diagnosis and control of the disease. 2020 , 6, 36		1
128	Development and Optimization of Chromosomally-Integrated Fluorescent Reporter Constructs. <i>Frontiers in Microbiology</i> , 2020 , 11, 591866	5.7	1
127	Accumulation of TB-Active Compounds in Murine Organs Relevant to Infection by. 2020 , 11, 724		3
126	Drug-Resistant Tuberculosis 2020: Where We Stand. 2020 , 10, 2153		25
125	For the Greater (Bacterial) Good: Heterogeneous Expression of Energetically Costly Virulence Factors. 2020 , 88,		3
124	Effects of host-directed therapies on the pathology of tuberculosis. 2020 , 250, 636-646		15
123	Reduced susceptibility and resistance to bedaquiline in clinical M. tuberculosis isolates. 2020 , 80, 527-535		16
122	Proteomic Profiling Reveals the Architecture of Granulomatous Lesions Caused by Tuberculosis and Complex Lung Disease. <i>Frontiers in Microbiology</i> , 2019 , 10, 3081	5.7	7

121	Digital Image Analysis of Heterogeneous Tuberculosis Pulmonary Pathology in Non-Clinical Animal Models using Deep Convolutional Neural Networks. 2020 , 10, 6047	6
120	FX11 limits growth and potentiates bactericidal activity of isoniazid through host-directed activity. 2020 , 13,	7
119	Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis. 2021 , 87, 140-151	4
118	The population genomics of within-host Mycobacterium tuberculosis. 2021 , 126, 1-9	2
117	Development of New Tuberculosis Drugs: Translation to Regimen Composition for Drug-Sensitive and Multidrug-Resistant Tuberculosis. 2021 , 61, 495-516	9
116	Exploiting Fluorescent Proteins to Understand Mycobacterium tuberculosis Biology. 2021 , 2314, 365-383	2
115	Perspectives and Advances in the Understanding of Tuberculosis. 2021 , 16, 377-408	5
114	An overview of metal homeostasis pathways during infection. 2021 , 2, uqab001	2
113	Predictive modeling to study the treatment-shortening potential of novel tuberculosis drug regimens, towards bundling of preclinical data. 2021 ,	3
112	Systematic measurement of combination drug landscapes to predict in vivo treatment outcomes for tuberculosis.	1
111	Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review. 2021 , 11, 624607	8
110	Aggregated Mycobacterium tuberculosis enhances the inflammatory response.	
109	One Size Fits All? Not in Modeling of Tuberculosis Chemotherapeutics. 2021 , 11, 613149	2
108	Load in Host Cells and the Antibacterial Activity of Alveolar Macrophages Are Linked and Differentially Regulated in Various Lung Lesions of Patients with Pulmonary Tuberculosis. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3 2
107	Mycobacterium tuberculosis modifies cell wall carbohydrates during biofilm growth with a concomitant reduction in complement activation.	
106	Longer-Term Omega-3 LCPUFA More Effective Adjunct Therapy for Tuberculosis Than Ibuprofen in a C3HeB/FeJ Tuberculosis Mouse Model. <i>Frontiers in Immunology</i> , 2021 , 12, 659943	8.4 1
105	Antitubercular Agents. 1-110	
104	A non-canonical type 2 immune response coordinates tuberculous granuloma formation and epithelialization. 2021 , 184, 1757-1774.e14	17

103	Establishment of a Patient-Derived, Magnetic Levitation-Based, 3D Spheroid Granuloma Model for Human Tuberculosis.		
102	Five-year microevolution of a multidrug-resistant Mycobacterium tuberculosis strain within a patient with inadequate compliance to treatment. 2021 , 21, 394		2
101	-3 long-chain PUFA promote antibacterial and inflammation-resolving effects in -infected C3HeB/FeJ mice, dependent on fatty acid status. 2021 , 1-14		2
100	Zinc limitation triggers anticipatory adaptations in Mycobacterium tuberculosis. <i>PLoS Pathogens</i> , 2021 , 17, e1009570	7.6	7
99	Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide. 2021 , 12, 3816		6
98	Elucidating the Antimycobacterial Mechanism of Action of Decoquinone Derivative RMB041 Using Metabolomics. 2021 , 10,		5
97	Targeting Mycobacterium tuberculosis response to environmental cues for the development of effective antitubercular drugs. 2021 , 19, e3001355		2
96	Beneficial effect of long-chain n-3 polyunsaturated fatty acid supplementation on tuberculosis in mice. 2021 , 170, 102304		2
95	Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0058321	5.9	4
94	Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis.		
93	Shotgun proteomic profiling of dormant, 'non-culturable' Mycobacterium tuberculosis.		
92	Systematic measurement of combination-drug landscapes to predict in vivo treatment outcomes for tuberculosis. 2021 , 12, 1046-1063.e7		4
91	The Sputum Microbiome in Pulmonary Tuberculosis and Its Association With Disease Manifestations: A Cross-Sectional Study. <i>Frontiers in Microbiology</i> , 2021 , 12, 633396	5.7	3
90	Establishment of a Patient-Derived, Magnetic Levitation-Based, Three-Dimensional Spheroid Granuloma Model for Human Tuberculosis. 2021 , 6, e0055221		1
89	Procollagen C-proteinase enhancer-1 (PCPE-1), a potential biomarker and therapeutic target for fibrosis. 2021 , 11, 100062		5
88	Mesenchymal Stem Cells: A Hidden Arsenal for Mtb Persistence, Resuscitation, and Reactivation. 2019 , 301-314		1
87	The tryptophan biosynthetic pathway is essential for Mycobacterium tuberculosis to cause disease. 2020 , 48, 2029-2037		8
86	Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 ,	5.9	3

85	Osteoarticular Tuberculosis-Brief Review of Clinical Morphological and Therapeutic Profiles. 2017 , 43, 171-190		7
84	Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach. 2017 , 13, e1005650		37
83	The Functional Response of B Cells to Antigenic Stimulation: A Preliminary Report of Latent Tuberculosis. 2016 , 11, e0152710		20
82	Intracellular growth of after macrophage cell death leads to serial killing of host cells. 2017 , 6,		51
81	Potential of P2RX7 as a host-directed strategy for control of mycobacterial infection. 2019 , 8,		25
80	COVID-19 Lung Pathogenesis in SARS-CoV-2 Autopsy Cases. <i>Frontiers in Immunology</i> , 2021 , 12, 735922	8.4	8
79	modifies cell wall carbohydrates during biofilm growth with a concomitant reduction in complement activation. 2021 , 7, 100065		3
78	On-Slide Heat Sterilization Enables Mass Spectrometry Imaging of Tissue Infected with High-Threat Pathogens Outside of Biocontainment: A Study Directed at. 2021 , 32, 2664-2674		0
77	Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis. <i>Frontiers in Immunology</i> , 2021 , 12, 733853	8.4	1
76	Local Pulmonary Host-Directed Therapies for Tuberculosis via Aerosol Delivery. 307-323		
75	MicroRNA AND TUBERCULOSIS. 2018 , 8, 309-315		1
74	Tuberculous and Nontuberculous Mycobacterial Infections. 2019 , 201-206		
73	Treatment-shortening effect of a novel regimen combining high-dose rifapentine and clofazimine in pathologically distinct mouse models of tuberculosis.		
72	Inhibition of host Lactate dehydrogenase A by a small-molecule limits <i>Mycobacterium tuberculosis</i> growth and potentiates bactericidal activity of isoniazid.		
71	Game Theory Applications in Host-Microbe Interactions: <i>Mycobacterium tuberculosis</i> infection as an example.		1
70	Multimodal profiling of lung granulomas reveals cellular correlates of tuberculosis control.		4
69	Intracellular localisation of <i>Mycobacterium tuberculosis</i> affects antibiotic efficacy.		
68	A virtual host model of <i>Mycobacterium tuberculosis</i> infection identifies early immune events as predictive of infection outcomes.		

67	Spatial relationships of intra-lesion heterogeneity in <i>Mycobacterium tuberculosis</i> microenvironment, replication status, and drug efficacy.		
66	A chemical-genetic map of the pathways controlling drug potency in <i>Mycobacterium tuberculosis</i> .		0
65	Aggregated Enhances the Inflammatory Response.. <i>Frontiers in Microbiology</i> , 2021 , 12, 757134	5.7	2
64	A virtual host model of <i>Mycobacterium tuberculosis</i> infection identifies early immune events as predictive of infection outcomes.. <i>Journal of Theoretical Biology</i> , 2022 , 111042	2.3	0
63	Prevalence and Risk Factors of Subclinical Tuberculosis in a Low-Incidence Setting in China.. <i>Frontiers in Microbiology</i> , 2021 , 12, 731532	5.7	1
62	Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in <i>Mycobacterium tuberculosis</i> .. <i>PLoS Pathogens</i> , 2022 , 18, e1009862	7.6	2
61	A Dual Role of Heme Oxygenase-1 in Tuberculosis.. <i>Frontiers in Immunology</i> , 2022 , 13, 842858	8.4	0
60	Pharmacodynamics and the Bactericidal Activity of Bedaquiline in Pulmonary Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , AAC0163621	5.9	1
59	Immunometabolism of Myeloid-Derived Suppressor Cells: Implications for Infection and Insights from Tumor Biology.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	0
58	Spatial relationships of intra-lesion heterogeneity in <i>Mycobacterium tuberculosis</i> microenvironment, replication status, and drug efficacy.. <i>PLoS Pathogens</i> , 2022 , 18, e1010459	7.6	0
57	In the Thick of It: Formation of the Tuberculous Granuloma and Its Effects on Host and Therapeutic Responses.. <i>Frontiers in Immunology</i> , 2022 , 13, 820134	8.4	0
56	Visualizing Pyrazinamide Action by Live Single-Cell Imaging of Phagosome Acidification and <i>Mycobacterium tuberculosis</i> pH Homeostasis.. <i>MBio</i> , 2022 , e0011722	7.8	0
55	Two-component sensor histidine kinases of <i>Mycobacterium tuberculosis</i> : beacons for niche navigation.. <i>Molecular Microbiology</i> , 2022 ,	4.1	0
54	Assessment of the efficacy of clofazimine alone and in combination with primary agents against <i>Mycobacterium tuberculosis</i> in vitro.. <i>Journal of Global Antimicrobial Resistance</i> , 2022 ,	3.4	0
53	Types and functions of heterogeneity in mycobacteria.. <i>Nature Reviews Microbiology</i> , 2022 ,	22.2	1
52	Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: implications for dose selection.. <i>European Journal of Pharmaceutical Sciences</i> , 2022 , 106163	5.1	0
51	The contribution of microfluidics to the fight against tuberculosis. <i>Nanotechnology Reviews</i> , 2021 , 11, 40-54	6.3	1
50	Visualizing pyrazinamide action by live single cell imaging of phagosome acidification and <i>Mycobacterium tuberculosis</i> pH homeostasis.		

49	The Transcriptomic Blueprint of in the Lung.. <i>Frontiers in Immunology</i> , 2021 , 12, 763364	8.4	0
48	A Perspective on the Success and Failure of BCG.. <i>Frontiers in Immunology</i> , 2021 , 12, 778028	8.4	1
47	Interleukin-13 overexpressing mice represent an advanced pre-clinical model for detecting the distribution of anti-mycobacterial drugs within centrally necrotizing granulomas. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , AAC0158821	5.9	1
46	Data_Sheet_1.docx. 2018 ,		
45	Image_1.JPEG. 2020 ,		
44	Image_2.JPEG. 2020 ,		
43	Image_3.JPEG. 2020 ,		
42	Image_4.JPEG. 2020 ,		
41	Image_5.JPEG. 2020 ,		
40	Image_6.JPEG. 2020 ,		
39	Image_7.JPEG. 2020 ,		
38	Image_8.JPEG. 2020 ,		
37	Table_1.XLSX. 2020 ,		
36	Table_2.XLSX. 2020 ,		
35	Table_3.XLSX. 2020 ,		
34	Table_4.XLSX. 2020 ,		
33	Data_Sheet_1.docx. 2019 ,		
32	Data_Sheet_1.PDF. 2019 ,		

31	Data_Sheet_2.ZIP. 2019 ,		
30	Table_1.xls. 2019 ,		
29	Table_2.XLS. 2019 ,		
28	Data_Sheet_1.PDF. 2020 ,		
27	Game theory applications in host-microbe interactions toward disease manifestation: infection as an example.. <i>Iranian Journal of Basic Medical Sciences</i> , 2021 , 24, 1324-1335	1.8	0
26	Anti-tuberculosis treatment strategies and drug development: challenges and priorities.. <i>Nature Reviews Microbiology</i> , 2022 ,	22.2	8
25	Multimodal profiling of lung granulomas in macaques reveals cellular correlates of tuberculosis control.. <i>Immunity</i> , 2022 ,	32.3	7
24	A century of attempts to develop an effective tuberculosis vaccine: Why they failed?. <i>International Immunopharmacology</i> , 2022 , 109, 108791	5.8	
23	High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: evidence for heteroresistance.		
22	Deciphering the Proteomic Landscape of Mycobacterium tuberculosis in Response to Acid and Oxidative Stresses. <i>ACS Omega</i> ,	3.9	0
21	Shotgun proteomic profiling of dormant, Non-culturable Mycobacterium tuberculosis. 2022 , 17, e0269847		
20	Diagnosis of Extrapulmonary tuberculosis by cartridge-based nucleic acid amplification test (CBNAAT) and detection of rifampicin resistance on fine-needle aspiration samples: An institution-based study. 2022 , 19, 448		0
19	Navigating the cellular landscape in tissue: Recent advances in defining the pathogenesis of human disease. 2022 , 20, 5256-5263		0
18	Comparing Current and Next-Generation Humanized Mouse Models for Advancing HIV and HIV/Mtb Co-Infection Studies. 2022 , 14, 1927		2
17	Spatial multiomic profiling reveals the novel polarization of foamy macrophages within necrotic granulomatous lesions developed in lungs of C3HeB/FeJ mice infected with Mycobacterium tuberculosis. 12,		0
16	NAD(H) homeostasis is essential for host protection mediated by glycolytic myeloid cells in tuberculosis.		1
15	Drug resistant tuberculosis: Implications for transmission, diagnosis, and disease management. 12,		0
14	The evolving biology of Mycobacterium tuberculosis drug resistance. 12,		1

- 13 Isolated synovial sheath tuberculosis: MRI features. **2022**, 15, e251556 ○
- 12 Unraveling the mechanisms of intrinsic drug resistance in *Mycobacterium tuberculosis*. 12, ○
- 11 In silico identification and synthesis of a multi-drug loaded MOF for treating tuberculosis. **2022**, 352, 242-255 ○
- 10 Distinct contributions of the innate immune receptors TLR2 and RP105 to formation and architecture of structured lung granulomas in mice infected with *Mycobacterium tuberculosis*. ○
- 9 Clinically encountered growth phenotypes of tuberculosis-causing bacilli and their in vitro study: A review. 12, ○
- 8 Advances in the design of combination therapies for the treatment of tuberculosis. 1 ○
- 7 Tools to develop antibiotic combinations that target drug tolerance in *Mycobacterium tuberculosis*. 12, ○
- 6 Bone and Joint Tuberculosis. **2023**, 803-815 ○
- 5 Lung microenvironments harbor *Mycobacterium tuberculosis* phenotypes with distinct treatment responses. ○
- 4 The clinical-stage drug BTZ-043 accumulates in tuberculosis lesions and efficiently acts against *Mycobacterium tuberculosis*. ○
- 3 In silico agent-based modeling approach to characterize multiple in vitro tuberculosis infection models. ○
- 2 Multiomics Integration of Tuberculosis Pathogenesis. **2023**, 937-967 ○
- 1 High rifampicin peak plasma concentrations accelerate the slow phase of bacterial decline in tuberculosis patients: Evidence for heteroresistance. **2023**, 19, e1011000 ○